Otsuka Holdings (4578.T)

Executive Summary

Otsuka Holdings is a Japanese healthcare conglomerate with a strong focus on central nervous system (CNS) therapeutics, complemented by a diversified portfolio in pharmaceuticals and nutraceuticals. The company's flagship products include the antipsychotic Abilify (aripiprazole) and the follow-on Rexulti (brexpiprazole), which together generate significant revenue. However, Abilify faces generic erosion, and Otsuka is investing in pipeline assets such as AVP-786 for Alzheimer's disease agitation and digital therapeutics like Rejoyn for major depressive disorder. The company also holds a robust nutraceutical business with brands like Pocari Sweat. While Otsuka maintains a stable financial profile and global reach, its growth trajectory hinges on successful pipeline execution and market expansion of newer products. Overall, Otsuka presents a moderate conviction opportunity given its established CNS franchise and emerging digital health initiatives.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on AVP-786 for Alzheimer's agitation40% success
• Q4 2026International expansion of Rejoyn digital therapeutic70% success
• TBDNew partnership or in-license for CNS pipeline asset50% success